home / stock / pyxs / pyxs short
Short Information | Pyxis Oncology Inc. (NASDAQ:PYXS)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 1,874,837 |
Total Actual Volume | 19,950,147 |
Short Trends | |
---|---|
Cover Days | 20 |
Short Days | 0 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 93,742 |
Average Short Percentage | 13.55% |
Is there a PYXS Short Squeeze or Breakout about to happen?
See the PYXS Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
07-19-2024 | $3.25 | $3.48 | $3.5 | $3.23 | 666,494 | 120,248 | 18.04% |
07-18-2024 | $3.25 | $3.24 | $3.41 | $3.17 | 436,144 | 55,379 | 12.7% |
07-17-2024 | $3.6 | $3.27 | $3.6399 | $3.225 | 826,370 | 69,640 | 8.43% |
07-16-2024 | $3.22 | $3.56 | $3.58 | $3.195 | 853,375 | 87,118 | 10.21% |
07-15-2024 | $3.18 | $3.2 | $3.28 | $3.169 | 374,327 | 53,438 | 14.28% |
07-12-2024 | $3.04 | $3.15 | $3.3 | $2.97 | 1,197,474 | 189,153 | 15.8% |
07-11-2024 | $3.03 | $2.97 | $3.1999 | $2.87 | 813,925 | 97,357 | 11.96% |
07-10-2024 | $2.87 | $2.96 | $3.09 | $2.865 | 934,688 | 95,037 | 10.17% |
07-09-2024 | $2.83 | $2.83 | $2.89 | $2.81 | 421,477 | 51,079 | 12.12% |
07-08-2024 | $2.91 | $2.87 | $2.99 | $2.87 | 491,255 | 82,737 | 16.84% |
07-05-2024 | $2.88 | $2.9 | $2.98 | $2.8101 | 513,437 | 77,385 | 15.07% |
07-03-2024 | $2.93 | $2.88 | $2.95 | $2.825 | 286,156 | 58,285 | 20.37% |
07-02-2024 | $3.18 | $2.94 | $3.18 | $2.92 | 893,218 | 55,556 | 6.22% |
07-01-2024 | $3.28 | $3.2 | $3.29 | $3.045 | 766,942 | 136,103 | 17.75% |
06-28-2024 | $3.22 | $3.31 | $3.5 | $3.13 | 7,130,601 | 120,646 | 1.69% |
06-27-2024 | $3.15 | $3.21 | $3.36 | $3.11 | 485,209 | 78,716 | 16.22% |
06-26-2024 | $3.04 | $3.21 | $3.21 | $2.95 | 668,940 | 165,127 | 24.68% |
06-25-2024 | $3.19 | $3.06 | $3.29 | $3.04 | 705,795 | 141,708 | 20.08% |
06-24-2024 | $3.36 | $3.19 | $3.395 | $3.15 | 275,265 | 24,041 | 8.73% |
06-21-2024 | $3.4 | $3.37 | $3.43 | $3.3 | 1,209,055 | 116,084 | 9.6% |
News, Short Squeeze, Breakout and More Instantly...
BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effecti...
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a...
PYX-201 Phase 1 trial clinical readout on track for fall of 2024 Executive Leadership Team expanded with the appointment of Stephen Worsley as Senior Vice President, Chief Business Officer PYX-106 Phase 1 trial clinical readout on track for 2H 2024 Expected cash runway i...